ClinicalTrials.gg
CompletedNCT03856827Updated Aug 16, 2024

A Study of IW-6463 in Healthy Volunteers

A Phase 1 interventional study of IW-6463 and Matching Placebo in Other, sponsored by Tisento Therapeutics. Completed at 1 site in Netherlands. Per ClinicalTrials.gov, last updated 2024-08-16.

Sponsored by Tisento Therapeutics · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Oct 2019, 7 years ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
110
Allocation
Randomized
Sex
All
01

Study summary

Stage 1: To assess the safety and tolerability of single-ascending-dose levels of IW-6463 tablets when administered orally to healthy subjects

Stage 2: To assess the safety and tolerability of multiple-ascending-dose levels of IW-6463 tablets administered orally to healthy subjects

Stage 3: To assess the safety and tolerability of a single dose of IW-6463 when administered to health subjects in fed vs fasted states and explore the effects of food on IW-6463 pharmacokinetics (PK)

02

Conditions studied

  • Other
03

In context

Lead sponsor

Tisento Therapeutics is the lead sponsor of 7 studies on the registry; none are open to participants now.

Of its 7 completed or terminated interventional studies of FDA-regulated products, 2 (29%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is an ambulatory adult between 18 and 64 years old at the screening visit with the exception of the elderly cohort, who must be 65 years or older at the screening visit.
  • Subject is in good health and has no findings on physical examination
  • Women of must have a negative pregnancy test at the time of check-in and must agree to use protocol-specified throughout the duration of the study and for 3 months after the final dose of study drug
  • Men must agree to use protocol-specified contraception and also to not donate sperm throughout the study and for 3 months after the final dose of study drug
  • Other inclusion criteria per protocol

Exclusion criteria

Exclusion Criteria:

  • Any active or unstable medical condition
  • Use of any prescribed or non-prescribed medication
  • Other exclusion criteria per protocol
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
110 participants (actual)

Study arms

  • Experimental
    IW-6463

    IW-6463 tablets administered orally as single ascending doses, multiple ascending daily doses, and single doses with or without food

    Drug: IW-6463

  • Placebo comparator
    Placebo

    Matching placebo tablets administered orally

    Drug: Matching Placebo

Interventions

  • IW-6463 Tablet

    Also known as: CY6463, zagociguat

  • DrugMatching Placebo

    Matching Placebo Tablet

06

What researchers measure

Primary outcomes

  1. After single ascending doses, number of subjects with treatment-emergent adverse events (TEAEs) in the IW-6463 dose-level cohorts vs the (pooled) placebo group.

    Time frame: Up to 9 days

  2. After multiple ascending doses, number of subjects with TEAEs in the IW-6463 dose-level cohorts vs the (pooled) placebo group.

    Time frame: Up to 32 days

  3. After a single dose, number of subjects with TEAEs in the fed vs fasted dosing period

    Time frame: Up to 28 days

  4. Plasma concentration of IW-6463 after single-dose administration under fed vs fasted conditions

    Time frame: Up to 21 days

07

Study locations

1 site
  • Centre for Human Drug Research
    Leiden, 2333 CL, Netherlands
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2019 to primary completion in Oct 2019, 8 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 20, 2019
First posted
Feb 27, 2019
StartActual
Feb 6, 2019
Primary completionActual
Oct 22, 2019
CompletionActual
Oct 22, 2019
Last update
Aug 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03856827
Lead sponsor
Tisento Therapeutics
Responsible party
Sponsor
First posted
Feb 27, 2019
Start date
Feb 6, 2019
Primary completion
Oct 22, 2019
Completion
Oct 22, 2019
Last update
Aug 16, 2024

Study contacts

Chad Glasser, PharmD
study director · Cyclerion Therapeutics, Inc
Geert J Groeneveld, MSc
principal investigator · Centre for Human Drug Research

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zagociguat

Start the discussion